Download PDF
Zeitschrift für Phytotherapie 2020; 41(01): 32-36
DOI: 10.1055/a-1015-5202
Praxis

Silymarin-Extrakt aus Silybum marianum (L.) Gaertn. gegen alimentär-toxische Leberschäden?

Ein Update
Detmar Jobst
,
Karin Kraft
,
Björn Feistel
,
Robert Fürst
› Further Information
    Permissions and Reprints

Die nichtalkoholische Fettlebererkrankung (NAFLD) zählt zu den häufigsten Lebererkrankungen weltweit. Wesentliche Risikofaktoren sind eine durch Fehl- und Überernährung hervorgerufene Adipositas, Fettstoffwechselstörungen und Insulinresistenz. Silymarin-Präparate zeigten hier in jüngeren Studien uneinheitliche Ergebnisse.



Publication History

Article published online:
27 February 2020

© Georg Thieme Verlag KG
Stuttgart · New York

 

  • Literatur

  • 1 Younossi Z, Tacke F, Arrese M. et al. Global perspectives of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 2019; 69: 2672-2682
    CrossrefPubMedGoogle Scholar
  • 2 Bedogni G, Miglioli L, Masutti F. et al. Incidence and natural course of fatty liver in the general population: the Dionysos study. Hepatology 2007; 46: 1387-1391
    CrossrefPubMedGoogle Scholar
  • 3 Warpakowski A. Hepatologie: Patienten mit Progressionsrisiko identifizieren und therapieren. Deutsches Ärzteblatt 2019; , 116: 31-32
    PubMedGoogle Scholar
  • 4 Schuppan D, Schattenberg JM. Non-alcoholic steatohepatitis: Pathogenesis and novel therapeutic approaches. J Gastroenterol Hepatol 2013; 28 (Suppl. 1): 68-76
    PubMedGoogle Scholar
  • 5 Chalasani N, Younossi Z, Lavine JE. et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2012; 55: 2005-2023
    CrossrefPubMedGoogle Scholar
  • 6 Promrat K, Kleiner DE, Niemeier HM. et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010 51. 121-129
    PubMedGoogle Scholar
  • 7 Centis E, Moscatiello S, Bugianesi E. et al. Stage of change and motivation to healthier lifestyle in non-alcoholic fatty liver disease. J Hepatol 2013; 58: 771-777
    CrossrefPubMedGoogle Scholar
  • 8 Del Ben M, Polimeni L, Baratta F. et al. Modern approach to the clinical management of non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20: 8341-8350
    CrossrefPubMedGoogle Scholar
  • 9 Committee on Herbal Medicinal Products (HMPC). Assessment Report on Silybum marianum (L.) Gaertn., fructus. London: European Medicines Agency; 2018. . EMA / HMPC / 294188 / 2013
    Google Scholar
  • 10 Fuchs EC, Gressne AM, Weyhenmayer R. et al. Identification of the antifibrogenic properties of silibinin: effect on TGF-b and matrix gene expression of hepatic stellate cells. Hepatology 1995; 22 (Suppl. S4): 286A
    PubMedGoogle Scholar
  • 11 Boigk G, Stroedter L, Herbst H. et al. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 1997; 26: 643-649
    CrossrefPubMedGoogle Scholar
  • 12 Wah Kheong C, Nik Mustapha NR, Mahadeva S. A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2017; 15: 1940-1949 .e8
    CrossrefPubMedGoogle Scholar
  • 13 Committee on Herbal Medicinal Products (HMPC). European Union Herbal Monograph on Silybum marianum (L.) Gaertn., fructus. London: European Medicines Agency;; 2018. . EMA / HMPC / 294187 / 2013
    Google Scholar
  • 14 Abenavoli L, Capasso R, Milic N, Capasso F. Milk thistle in liver diseases: past, present, future. Phytother Res 2010; 24: 1423-1432
    CrossrefPubMedGoogle Scholar
  • 15 Mengs U, Pohl RT, Mitchell T. Legalon® SIL: the antidote of choice in patients with acute hepatotoxicity from amatoxin poisoning. Curr Pharm Biotechnol 2012; 13: 1964-1970
    CrossrefPubMedGoogle Scholar
  • 16 Wellington K, Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs 2001; 15: 465-489
    CrossrefPubMedGoogle Scholar
  • 17 Saller R, Brignoli R, Melzer J. et al. An updated systematic review with meta-analysis for the clinical evidence of silymarin. Forsch Komplementmed 2008; 15: 9-20
    CrossrefPubMedGoogle Scholar
  • 18 Bunout D, Hirsch S, Petermann M. et al. Controlled study of the effect of silymarin on alcoholic liver disease. Rev Med Chil 1992; 120: 1370-1375
    PubMedGoogle Scholar
  • 19 Parés A, Planas R, Torres M. et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J Hepatol 1998; 28: 615-621
    CrossrefPubMedGoogle Scholar
  • 20 Cacciapuoti F, Scognamiglio A, Palumbo R. et al. Silymarin in non alcoholic fatty liver disease. World J Hepatol 2013; 5: 109-113
    CrossrefPubMedGoogle Scholar
  • 21 Solhi H, Ghahremani R, Kazemifar AM, Yazdi ZH. Silymarin in treatment of non-alcoholic steatohepatitis: A randomized clinical trial. Caspian J Intern Med 2014; 5: 9-12
    PubMedGoogle Scholar
  • 22 Sorrentino G, Crispino P, Coppola D, De Stefano G. Efficacy of lifestyle changes in subjects with non-alcoholic liver steatosis and metabolic syndrome may be improved with an antioxidant nutraceutical: a controlled clinical study. Drugs R D 2015; 15: 21-25
    CrossrefPubMedGoogle Scholar
  • 23 Zündorf I, Fürst R. Leber- / Galleleiden – können Pflanzen helfen?. Pharmakon 2019; 7: 410-421
    PubMedGoogle Scholar